Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;5(8):1211-20.
doi: 10.2217/fon.09.106.

Nonsteroidal Selective Androgen Receptor Modulator Ostarine in Cancer Cachexia


Nonsteroidal Selective Androgen Receptor Modulator Ostarine in Cancer Cachexia

Mihail F Zilbermint et al. Future Oncol. .


Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1.4 million patients diagnosed with cancer each year in the USA. This condition is characterized by progressive deterioration of a patient's nutritional status, weight loss, anorexia, diminished quality of life and increased mortality and morbidity. Current therapy with progestational, anti-inflammatory and anabolic agents is often ineffective and has a large number of undesirable effects. The newly developed nonsteroidal selective androgen receptor modulator Ostarine has demonstrated promising results in Phase I and II clinical trials, increasing total lean body mass, enhancing functional performance and decreasing total tissue percent fat. This selective androgen receptor modulator may have the ability to perform as a potent anabolic agent with minimal side effects on other organs (prostate and hair follicles), thus presenting a new strategy in managing cancer cachexia. However, more extensive data is required before its efficacy is confirmed.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

LinkOut - more resources